Background: Vatarakta vis-á-vis gout is a common condition in both primary care and specialist practice. Gout is a systemic disease characterized by manifestations of chronic underlying hyperuricemia, resulting in the deposition of monosodium urate crystals in various tissues. Gout is the most common of the crystal induced arthritis due to disturbed uric acid metabolism and precipitation of urate crystals in extracellular space of joints, periarticular tissue, bones, and other organs.

Aim and objective: To explore the therapeutic efficacy and safety of Amrita Guggulu and Pinda Taila in the management of hyperuricemia in gout (Vatarakta) patients.

Materials and methods: A total of 100 cases (25–65 years) of primary gouty arthritis fulfilling the diagnostic criteria as recommended by the American College of Rheumatology were selected for the present study from outpatient department of the Central Ayurveda Research Institute for Respiratory Disorders Patiala and Regional Ayurveda Research Institute for Urinary Disorders, Jammu, India, irrespective of their sex, religion, and socioeconomic status. Only those patients who presented themselves with at least 6 of 12 criteria of American College of Rheumatology (1977) were selected for the clinical trial. Amrita Guggulu was given 1000 mg twice daily orally and Pinda Taila was applied locally 10 mL twice daily for 84 days.

Results: The trial therapy was assessed based on the improvement in clinical features, Visual Analog Scale (VAS) score, Patient’s Global Assessment Scale score, Physician’s Global Assessment Scale Score, SF-36 Health Survey Score for quality of life (QOL), and biochemical parameters. Each patient was subjected to routine blood test, serum uric acid, liver function tests, and renal function tests before treatment, after 28 days of treatment, and after 84 days of treatment. The trial combination showed statistically significant improvement in the clinical manifestations, QOL as well as reduction in marker of hyperuricemia, i.e., serum uric acid; the mean serum uric acid at the baseline was 7.76 mg/dL, which was reduced to 6.50 mg/dL after the trial period of 84 days. There was also decrease in the level of VAS score, Patient’s Global Assessment Scale score, and Physician’s Global Assessment Scale score. There were no impairment in liver function test and renal function test, indicating the good safety profile of trial therapy.